Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis

被引：47

作者：

Baghaei, Kaveh ^{[1
,2
]}

Mazhari, Sogol ^{[1
]}

Tokhanbigli, Samaneh ^{[1
]}

Parsamanesh, Gilda ^{[1
]}

Alavifard, Helia ^{[1
]}

Schaafsma, Dedmer ^{[3
]}

Ghavami, Saeid ^{[4
,5
,6
,7
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Basic & Mol Epidemiol Gastrointestinal Disorders, Tehran 1985717413, Iran

[2] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Gastroenterol & Liver Dis Res Ctr, Tehran 1985717413, Iran

[3] Sci Impact, Winnipeg, MB, Canada

[4] Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada

[5] Univ Manitoba, Canc Care Manitoba, Res Inst Oncol & Hematol, Winnipeg, MB R3E 0V9, Canada

[6] Univ Manitoba, Children Hosp Res Inst Manitoba, Biol Breathing Theme, Winnipeg, MB R3E 0V9, Canada

[7] Katowice Sch Technol, Fac Med, PL-40555 Katowice, Poland

来源：

DRUG DISCOVERY TODAY | 2022年 / 27卷 / 04期

关键词：

Liver diseases; Extracellular signaling; Cell phenotype; Fibrogenic myofibroblasts; Autophagy; NF-KAPPA-B; HEDGEHOG SIGNALING INHIBITOR; TGF-BETA; ANTIFIBROTIC ACTIVITY; EXTRACELLULAR-MATRIX; RECEPTOR; AUTOPHAGY; PATHWAY; ANGIOGENESIS; PDGF;

D O I：

10.1016/j.drudis.2021.12.012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hepatic fibrosis is a manifestation of different etiologies of liver disease with the involvement of multiple mediators in complex network interactions. Activated hepatic stellate cells (aHSCs) are the central driver of hepatic fibrosis, given their potential to induce connective tissue formation and extracellular matrix (ECM) protein accumulation. Therefore, identifying the cellular and molecular pathways involved in the activation of HSCs is crucial in gaining mechanistic and therapeutic perspectives to more effectively target the disease. In addition to a comprehensive summary of our current understanding of the role of HSCs in liver fibrosis, we also discuss here the proposed therapeutic strategies based on targeting HSCs.

引用

页码：1044 / 1061

页数：18

共 50 条

[31] Emerging and Disease-Specific Mechanisms of Hepatic Stellate Cell Activation
Wallace, Michael C.
Friedman, Scott L.
Mann, Derek A.
SEMINARS IN LIVER DISEASE, 2015, 35 (02) : 107 - 118
[32] IL-17A Plays a Critical Role in the Pathogenesis of Liver Fibrosis through Hepatic Stellate Cell Activation
Tan, Zhongming
Qian, Xiaofeng
Jiang, Runqiu
Liu, Qianghui
Wang, Youjing
Chen, Chen
Wang, Xuehao
Ryffel, Bernhard
Sun, Beicheng
JOURNAL OF IMMUNOLOGY, 2013, 191 (04) : 1835 - 1844
[33] REDD1 attenuates hepatic stellate cell activation and liver fibrosis via inhibiting of TGF-β/Smad signaling pathway
Cho, Sam Seok
Lee, Ji Hyun
Kim, Kyu Min
Park, Eun Young
Ku, Sae Kwang
Cho, Il Je
Yang, Ji Hye
Ki, Sung Hwan
FREE RADICAL BIOLOGY AND MEDICINE, 2021, 176 : 246 - 256
[34] Suppressive effect of SATB1 on hepatic stellate cell activation and liver fibrosis in rats
He, Jiayi
Gong, Jin
Ding, Qiang
Tan, Qinghai
Han, Ping
Liu, Jingmei
Zhou, Zhenzhen
Tu, Wei
Xia, Yujia
Yan, Wei
Tian, Dean
FEBS LETTERS, 2015, 589 (12) : 1359 - 1368
[35] Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation
Guo, Ren
Jia, Xiaohui
Ding, Zhenbin
Wang, Gang
Jiang, Mengmeng
Li, Bing
Chen, Shanshan
Xia, Bingqing
Zhang, Qing
Liu, Jian
Zheng, Ruting
Gao, Zhaobing
Xie, Xin
THERANOSTICS, 2022, 12 (11): : 5220 - 5236
[36] Histone deacetylase inhibitor givinostat alleviates liver fibrosis by regulating hepatic stellate cell activation
Huang, He-Ming
Zhou, Xiao-Ru
Liu, Yan-Jun
Fan, Shi-Jie
Liao, Li-Ping
Huang, Jing
Shi, Cui-Cui
Yu, Liang
Pen, Jin-Jin
Luo, Cheng
Zhang, Yuan-Yuan
Li, Guang-Ming
MOLECULAR MEDICINE REPORTS, 2021, 23 (05)
[37] Neurotrophic factors stimulate the activation of hepatic stellate cells in liver fibrosis
Sun, Tian-Tian
Liu, Xu-Ling
Yang, Guang-Yue
Zhang, Wei
Tao, Le
Ma, Wen-Ting
Wu, Liu
Li, Qigen
Liu, Cheng
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 630 : 167 - 174
[38] Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era?
Chan, Yau-Tuen
Wang, Ning
Tan, Hor Yue
Li, Sha
Feng, Yibin
FRONTIERS IN PHARMACOLOGY, 2020, 11
[39] Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells
Chen, Ling
Li, Long
Chen, Junde
Li, Lei
Zheng, Zihan
Ren, Jie
Qiu, Yan
ONCOTARGET, 2015, 6 (40) : 42530 - 42540
[40] Endoplasmic reticulum stress in liver fibrosis: Mechanisms and therapeutic potential
Wang, Tiantian
Xia, Guoqing
Li, Xue
Gong, Mingxu
Lv, Xiongwen
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2025, 1871 (03):

← 1 2 3 4 5 →